Concepts (212)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV-1 | 17 | 2018 | 678 | 2.510 |
Why?
|
| HIV Infections | 17 | 2018 | 2207 | 1.380 |
Why?
|
| Endogenous Retroviruses | 5 | 2011 | 16 | 1.300 |
Why?
|
| Genotype | 8 | 2018 | 641 | 1.150 |
Why?
|
| RNA, Viral | 11 | 2011 | 287 | 0.940 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2010 | 69 | 0.670 |
Why?
|
| Viral Load | 11 | 2013 | 300 | 0.620 |
Why?
|
| Antiretroviral Therapy, Highly Active | 4 | 2007 | 219 | 0.610 |
Why?
|
| Genetic Variation | 2 | 2015 | 328 | 0.580 |
Why?
|
| Cytomegalovirus | 2 | 2013 | 38 | 0.550 |
Why?
|
| Evolution, Molecular | 2 | 2015 | 249 | 0.530 |
Why?
|
| Seminal Vesicle Secretory Proteins | 1 | 2013 | 7 | 0.480 |
Why?
|
| Cytomegalovirus Infections | 1 | 2013 | 22 | 0.470 |
Why?
|
| Semen | 1 | 2013 | 48 | 0.470 |
Why?
|
| Drug Resistance, Viral | 5 | 2018 | 60 | 0.390 |
Why?
|
| Parkinsonian Disorders | 1 | 2010 | 35 | 0.380 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2010 | 84 | 0.380 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2009 | 605 | 0.350 |
Why?
|
| Xylazine | 1 | 2008 | 2 | 0.330 |
Why?
|
| Needle Sharing | 1 | 2008 | 10 | 0.330 |
Why?
|
| Syringes | 1 | 2008 | 6 | 0.330 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2008 | 33 | 0.330 |
Why?
|
| Humans | 32 | 2020 | 34853 | 0.330 |
Why?
|
| Rhodamine 123 | 1 | 2008 | 3 | 0.330 |
Why?
|
| HIV Protease Inhibitors | 1 | 2008 | 22 | 0.320 |
Why?
|
| Sequence Analysis, DNA | 4 | 2018 | 455 | 0.310 |
Why?
|
| HIV | 1 | 2008 | 97 | 0.310 |
Why?
|
| Fluorescent Dyes | 1 | 2008 | 173 | 0.300 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2008 | 123 | 0.300 |
Why?
|
| Virus Replication | 4 | 2013 | 261 | 0.290 |
Why?
|
| Parkinson Disease | 1 | 2007 | 167 | 0.280 |
Why?
|
| T-Lymphocytes | 1 | 2008 | 341 | 0.260 |
Why?
|
| Adult | 13 | 2020 | 11034 | 0.250 |
Why?
|
| Gene Expression | 1 | 2007 | 639 | 0.240 |
Why?
|
| Hepatitis C | 3 | 2014 | 120 | 0.240 |
Why?
|
| Puerto Rico | 5 | 2018 | 1352 | 0.220 |
Why?
|
| Hepacivirus | 3 | 2010 | 59 | 0.210 |
Why?
|
| Flow Cytometry | 3 | 2008 | 392 | 0.210 |
Why?
|
| Child, Preschool | 2 | 2015 | 1318 | 0.200 |
Why?
|
| Saliva | 2 | 2020 | 97 | 0.200 |
Why?
|
| Young Adult | 6 | 2020 | 4012 | 0.180 |
Why?
|
| Male | 14 | 2020 | 18870 | 0.180 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2018 | 224 | 0.180 |
Why?
|
| Executive Function | 1 | 2020 | 47 | 0.180 |
Why?
|
| Molecular Epidemiology | 2 | 2018 | 49 | 0.180 |
Why?
|
| Middle Aged | 9 | 2020 | 9642 | 0.170 |
Why?
|
| History, 20th Century | 2 | 2010 | 110 | 0.170 |
Why?
|
| CD4-Positive T-Lymphocytes | 5 | 2009 | 251 | 0.170 |
Why?
|
| HIV Reverse Transcriptase | 3 | 2015 | 33 | 0.170 |
Why?
|
| Molecular Sequence Data | 5 | 2011 | 1490 | 0.160 |
Why?
|
| Child | 2 | 2015 | 2875 | 0.160 |
Why?
|
| Intracranial Hemorrhage, Traumatic | 1 | 2017 | 1 | 0.150 |
Why?
|
| Female | 12 | 2020 | 19873 | 0.150 |
Why?
|
| Seizures | 1 | 2017 | 67 | 0.150 |
Why?
|
| Mental Disorders | 1 | 2020 | 285 | 0.140 |
Why?
|
| Renal Dialysis | 1 | 2017 | 119 | 0.140 |
Why?
|
| Dominican Republic | 1 | 2015 | 20 | 0.130 |
Why?
|
| Bacteria | 1 | 2018 | 245 | 0.130 |
Why?
|
| Up-Regulation | 2 | 2008 | 490 | 0.130 |
Why?
|
| Alcohol Drinking | 1 | 2020 | 490 | 0.130 |
Why?
|
| Inflammation | 1 | 2020 | 577 | 0.130 |
Why?
|
| Anti-HIV Agents | 2 | 2013 | 394 | 0.130 |
Why?
|
| Interleukins | 1 | 2014 | 28 | 0.130 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 2 | 2005 | 55 | 0.130 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2008 | 214 | 0.130 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 2 | 2011 | 18 | 0.120 |
Why?
|
| Adolescent | 3 | 2018 | 5035 | 0.120 |
Why?
|
| NIH 3T3 Cells | 1 | 2013 | 60 | 0.120 |
Why?
|
| Virus Internalization | 1 | 2013 | 27 | 0.120 |
Why?
|
| Depression | 1 | 2020 | 664 | 0.120 |
Why?
|
| Aged | 4 | 2018 | 6448 | 0.110 |
Why?
|
| Mutation | 4 | 2018 | 1023 | 0.110 |
Why?
|
| DNA, Viral | 2 | 2010 | 295 | 0.100 |
Why?
|
| Viral Tropism | 1 | 2010 | 2 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 638 | 0.100 |
Why?
|
| Antigens, Viral | 1 | 2010 | 42 | 0.100 |
Why?
|
| Vaccines, Synthetic | 1 | 2010 | 72 | 0.100 |
Why?
|
| Germ-Line Mutation | 1 | 2009 | 51 | 0.090 |
Why?
|
| Polypyrimidine Tract-Binding Protein | 1 | 2009 | 5 | 0.090 |
Why?
|
| Genes, Immediate-Early | 1 | 2009 | 6 | 0.090 |
Why?
|
| Glioblastoma | 1 | 2009 | 49 | 0.090 |
Why?
|
| Antibodies, Viral | 2 | 2010 | 252 | 0.080 |
Why?
|
| Substance Abuse Detection | 1 | 2008 | 27 | 0.080 |
Why?
|
| Verapamil | 1 | 2008 | 6 | 0.080 |
Why?
|
| Saquinavir | 1 | 2008 | 3 | 0.080 |
Why?
|
| Simian immunodeficiency virus | 2 | 2005 | 56 | 0.080 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2009 | 108 | 0.080 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2008 | 75 | 0.080 |
Why?
|
| Ritonavir | 1 | 2008 | 14 | 0.080 |
Why?
|
| Vagina | 2 | 2005 | 81 | 0.080 |
Why?
|
| Calcium Channel Blockers | 1 | 2008 | 56 | 0.080 |
Why?
|
| Treatment Failure | 1 | 2007 | 65 | 0.080 |
Why?
|
| Colonic Neoplasms | 1 | 2009 | 181 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2009 | 200 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2006 | 555 | 0.080 |
Why?
|
| Cells, Cultured | 2 | 2009 | 1442 | 0.080 |
Why?
|
| Cocaine-Related Disorders | 1 | 2008 | 84 | 0.080 |
Why?
|
| Ionophores | 1 | 2007 | 12 | 0.080 |
Why?
|
| Ionomycin | 1 | 2007 | 9 | 0.080 |
Why?
|
| Poliovirus Vaccine, Inactivated | 1 | 2006 | 3 | 0.080 |
Why?
|
| Immunization Schedule | 1 | 2006 | 7 | 0.080 |
Why?
|
| Poliovirus Vaccine, Oral | 1 | 2006 | 3 | 0.080 |
Why?
|
| Astrocytoma | 1 | 2007 | 13 | 0.080 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2007 | 39 | 0.080 |
Why?
|
| HIV Seronegativity | 1 | 2007 | 38 | 0.070 |
Why?
|
| Program Evaluation | 1 | 2008 | 316 | 0.070 |
Why?
|
| Diamines | 1 | 2006 | 7 | 0.070 |
Why?
|
| Benzothiazoles | 1 | 2006 | 20 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 282 | 0.070 |
Why?
|
| Organic Chemicals | 1 | 2006 | 35 | 0.070 |
Why?
|
| Kinetics | 1 | 2007 | 650 | 0.070 |
Why?
|
| Staining and Labeling | 1 | 2006 | 100 | 0.070 |
Why?
|
| Fluorescence | 1 | 2006 | 117 | 0.070 |
Why?
|
| Quinolines | 1 | 2006 | 60 | 0.070 |
Why?
|
| Retroviruses, Simian | 1 | 2005 | 3 | 0.070 |
Why?
|
| Cloning, Molecular | 1 | 2006 | 310 | 0.070 |
Why?
|
| Mice | 2 | 2013 | 5668 | 0.070 |
Why?
|
| HIV Seropositivity | 1 | 2007 | 182 | 0.070 |
Why?
|
| Risk-Taking | 1 | 2008 | 435 | 0.060 |
Why?
|
| Morphine Dependence | 1 | 2004 | 25 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2006 | 528 | 0.060 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2013 | 185 | 0.060 |
Why?
|
| Hepatitis C Antibodies | 1 | 2004 | 9 | 0.060 |
Why?
|
| Longitudinal Studies | 1 | 2007 | 841 | 0.060 |
Why?
|
| Immunodominant Epitopes | 1 | 2004 | 27 | 0.060 |
Why?
|
| Antibody Formation | 1 | 2004 | 73 | 0.060 |
Why?
|
| Viral Envelope Proteins | 1 | 2004 | 77 | 0.060 |
Why?
|
| Base Sequence | 1 | 2006 | 932 | 0.060 |
Why?
|
| Treatment Outcome | 1 | 2007 | 1349 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 901 | 0.060 |
Why?
|
| Animals | 4 | 2013 | 14307 | 0.060 |
Why?
|
| Alcoholism | 1 | 2005 | 220 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 2333 | 0.050 |
Why?
|
| Substance-Related Disorders | 1 | 2008 | 685 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2007 | 2128 | 0.050 |
Why?
|
| Phylogeny | 3 | 2011 | 612 | 0.050 |
Why?
|
| Immune System | 1 | 2020 | 40 | 0.050 |
Why?
|
| Alcohol-Related Disorders | 1 | 2020 | 52 | 0.040 |
Why?
|
| Mouth | 1 | 2018 | 44 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2018 | 165 | 0.040 |
Why?
|
| Hematoma, Subdural, Acute | 1 | 2017 | 4 | 0.040 |
Why?
|
| Japan | 1 | 2017 | 296 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 2 | 2009 | 430 | 0.030 |
Why?
|
| Genes, pol | 2 | 2005 | 15 | 0.030 |
Why?
|
| Ribavirin | 1 | 2014 | 17 | 0.030 |
Why?
|
| Cytokines | 1 | 2018 | 569 | 0.030 |
Why?
|
| HIV Protease | 2 | 2005 | 21 | 0.030 |
Why?
|
| Interferons | 1 | 2014 | 34 | 0.030 |
Why?
|
| Macaca mulatta | 2 | 2005 | 122 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2014 | 80 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2014 | 155 | 0.030 |
Why?
|
| Incidence | 1 | 2017 | 882 | 0.030 |
Why?
|
| Alleles | 1 | 2014 | 284 | 0.030 |
Why?
|
| Prevalence | 1 | 2018 | 1425 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 968 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2014 | 148 | 0.030 |
Why?
|
| Jamaica | 1 | 2013 | 5 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2014 | 485 | 0.030 |
Why?
|
| Registries | 1 | 2014 | 330 | 0.030 |
Why?
|
| Amino Acid Sequence | 2 | 2005 | 1124 | 0.030 |
Why?
|
| Reverse Transcription | 1 | 2011 | 16 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 528 | 0.030 |
Why?
|
| Recombination, Genetic | 1 | 2011 | 90 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2017 | 1961 | 0.020 |
Why?
|
| Genome, Viral | 1 | 2011 | 103 | 0.020 |
Why?
|
| Antigenic Variation | 1 | 2010 | 9 | 0.020 |
Why?
|
| Viral Structural Proteins | 1 | 2010 | 16 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 1003 | 0.020 |
Why?
|
| Hepatitis C, Chronic | 1 | 2010 | 39 | 0.020 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2010 | 45 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 1 | 2009 | 12 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2009 | 18 | 0.020 |
Why?
|
| Pedigree | 1 | 2009 | 64 | 0.020 |
Why?
|
| Luciferases | 1 | 2009 | 62 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2009 | 105 | 0.020 |
Why?
|
| Ribonucleoproteins | 1 | 2009 | 29 | 0.020 |
Why?
|
| RNA Splicing | 1 | 2009 | 36 | 0.020 |
Why?
|
| India | 1 | 2009 | 82 | 0.020 |
Why?
|
| RNA Precursors | 1 | 2009 | 25 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2009 | 164 | 0.020 |
Why?
|
| Risk Factors | 1 | 2017 | 3414 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2010 | 649 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2009 | 161 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 424 | 0.020 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 2006 | 11 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2009 | 484 | 0.020 |
Why?
|
| Seroepidemiologic Studies | 1 | 2006 | 67 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2009 | 287 | 0.020 |
Why?
|
| Protein Binding | 1 | 2009 | 913 | 0.020 |
Why?
|
| CD4-CD8 Ratio | 1 | 2005 | 28 | 0.020 |
Why?
|
| Cell Line | 1 | 2009 | 1289 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 2561 | 0.020 |
Why?
|
| Cerebrospinal Fluid | 1 | 2004 | 18 | 0.020 |
Why?
|
| Blood | 1 | 2004 | 32 | 0.020 |
Why?
|
| Narcotics | 1 | 2004 | 28 | 0.020 |
Why?
|
| Candidiasis, Oral | 1 | 2004 | 23 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2005 | 150 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2004 | 249 | 0.020 |
Why?
|
| Viral Core Proteins | 1 | 2004 | 10 | 0.020 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2004 | 41 | 0.020 |
Why?
|
| Genes, Viral | 1 | 2004 | 62 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2004 | 257 | 0.020 |
Why?
|
| Morphine | 1 | 2004 | 80 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2004 | 122 | 0.020 |
Why?
|
| Epitopes | 1 | 2004 | 145 | 0.020 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2003 | 14 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 2003 | 51 | 0.010 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2003 | 28 | 0.010 |
Why?
|
| Infant | 1 | 2006 | 1014 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 445 | 0.010 |
Why?
|
| Peptides | 1 | 2004 | 308 | 0.010 |
Why?
|
| Time Factors | 1 | 2005 | 1681 | 0.010 |
Why?
|